W. Hiddemann - Böcker

This book provides a unique overview of the current applications of aclacinomycin A in malignant haematologic disorders, as single-agent therapy or together with other agents in combination regiments. Accounts are given of its action in myelodysplastic syndromes and of its efficacy in acute myeloid leukemias for the latter, one chapter presents the results of single-agent therapy in older patients, while four other studies describe the efficacy of aclacinomycin A combined with conventional or intermediate-dose cutosine arabinoside or etoposide in relapsed or refractory acute myeloid leukemia.

Following the major breakthroughs in the and frequent and thorough exchange of treatment of acute leukemias in the seven- information. Hence, it was felt that a spe- ties by the introduction of intensive combi- cial series of symposia should be devoted to nation regimens, therapeutic progress has "Pharmacokinetics and Management of slowed down and the impression of stagna- Relapsed and Refractory Disease" comple- menting the established meetings on "Prog- tion may even have occured. In contrast, the knowledge about the biology of leu- nostic Factors and Treatment Strategies" kemias is rapidly expanding and allows new which will proceed in parallel. It was the insights into the pathophysiology of the aim of the international symposium disease. Further improvements also come "ACUTE LEUKEMIAS - Pharmacokine- from a better understanding of the pharma- tics and Management of Relapsed and cokinetics and pharmacodynamics of cyto- Refractory Disease" to provide an update static drugs and their mechanisms of action. of the present knowledge in this area and to Hence, novel treatment modalities can be stimulate further developments.As a sign developed on a more solid basis and ration- for the closing distance between countries al. These achievements need to be comple- and the development of effective world- mented by effective eradiation wide cooperation this symposium emerged of residual disease or its permanent control and new from the joint efforts of the German AML approaches have been derived from recent Cooperative Group and the M. D.

Die Rubrik "Leser fragen, Experten antworten" in den Facharzt-Zeitschriften des Springer-Verlages stößt seit ihrer Einführung auf großes Interesse. Das vorliegende Buch stellt eine Zusammenfassung dieser Rubrik aus den unterschiedlichen Facharzt-Zeitschriften dar und spiegelt damit die Interdisziplinarität der Medizin wider. Alle Antworten wurden von den Autoren erneut überarbeitet und aktualisiert. Die Ordnung nach Fachgebieten ermöglicht ein systematisches Lesen.Eine Sammlung, die dem Leser den Einblick in die Diskussion fachfremder Themen ermöglicht und damit den Blick über den Tellerrand hinaus erleichtert.

Since 1987 Acute Leukemias (AL) has regularly reported on the state of the art in the rapidly growing, successful and exciting field of biology and management of these diseases. In this volume large multicenter clinical trials again form the solid basis for the investigation of leukemic cell biology, the detection of biologic subgroups, their differential response to alternative treatment strategies and the further development of therapy. In particular, this volume addresses mechanisms of chromosomal translocations and transcription factors, risk-adapted treatment strategies, differentiation therapy, secondary AL, special aspects in older patients, and adoptive immunotherapy. Besides the antileukemic approaches, supportive treatment with new antimicrobial substances and growth factors is updated. As a forum of worldwide activities in the field of AL this volume contains both exhaustive overviews on major clinical issues and preliminary data and hypotheses not previously published.